Neurology Service, Veterans Affairs Medical Center, Cleveland OH, USA.
Ann Neurol. 2010 May;67(5):676-80. doi: 10.1002/ana.21991.
We conducted a masked, crossover, therapeutic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patients (aged 28-61 years; 7 female; 3 multiple sclerosis [MS]; 6 post-stroke; 1 post-traumatic). Nystagmus was pendular in 6 patients (4 oculopalatal tremor; 2 MS) and jerk upbeat, hemi-seesaw, torsional, or upbeat-diagonal in each of the others. For the group, both drugs reduced median eye speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved visual acuity (p < 0.05). Each patient improved with 1 or both drugs. Side effects included unsteadiness with gabapentin and lethargy with memantine. Both drugs should be considered as treatment for acquired forms of nystagmus.
我们进行了一项针对获得性眼球震颤的掩蔽、交叉、治疗试验，比较了加巴喷丁（1200mg/天）和美金刚（40mg/天）在 10 名患者（年龄 28-61 岁；7 名女性；3 名多发性硬化症[MS]；6 名中风后；1 名创伤后）中的疗效。6 名患者的眼球震颤呈摆动性（4 名眼-腭震颤；2 名 MS），其余 4 名患者的眼球震颤呈急跳性上冲、半摆动、扭转或上冲对角线。对于该组患者，两种药物均降低了中位眼速（p<0.001），加巴喷丁降低了 32.8%，美金刚降低了 27.8%，并改善了视力（p<0.05）。每位患者均对 1 种或 2 种药物有改善。副作用包括加巴喷丁引起的不稳定和美金刚引起的昏睡。这两种药物都应被考虑作为治疗获得性眼球震颤的方法。
